The top 100 drugs: a 5-year outlook by therapeutic area, 2026–2031
$546bn of 2025 sales across 12 therapy areas, projected drug by drug with patent expiries, Medicare negotiated prices and new launches. See the method our ready-to-go reports use. Read the report →
Ready-to-go or built around your question
Ready-to-go
The standard report below, on any product in the catalogue. Fixed scope, fixed price, no scoping call.
- Global view plus EU5 and US detail
- Base, low and high scenarios, 2027–2031
- PDF report and Excel model
- Delivered in 5 business days
Portfolio pack
Five ready-to-go analyses ordered together: a therapy area, a competitor set or your own portfolio.
- Same standard scope per product
- One cross-product summary
- Delivered in 10 business days
Custom
Your markets, your question. For pipeline assets not yet approved, single-country deep-dives (Greece, Cyprus, the Balkans, any EU market), launch sequencing, in-licensing and deal screening.
- Scoping call and written proposal
- Your own scenarios and assumptions
- Timeline agreed in the proposal
The ready-to-go 5-year market analysis
- Executive summaryThe 5-year outlook in one page: peak-year range, key drivers and the risks that move it.
- Product and regulatory profileIndications, approvals and status in the EU and US, designations, label changes and exclusivity.
- Patient populationPrevalence, diagnosed and treated patients by market, from published epidemiology.
- Treatment landscapeStandard of care, guidelines and where the product sits in the treatment pathway.
- CompetitionMarketed competitors, late-stage pipeline, biosimilar and generic entry, and loss-of-exclusivity timing.
- Pricing and accessList-price and reimbursement context, HTA outcomes and access barriers by market.
- 5-year revenue scenariosBase, low and high cases for 2027–2031 by region, with uptake, share and price assumptions set out.
- Risks and catalystsUpcoming readouts, regulatory dates, patent events and policy changes that could change the forecast.
Sources: official regulator records (EMA, European Commission, FDA), company filings and reports, published literature and HTA decisions; each fact is referenced. Forecasts are modelled scenarios built on stated assumptions, not guarantees. Not investment advice.
Find your product
Every EU-authorised medicine in the EMA register and every FDA approval in our database. Not listed? Order it anyway: pipeline and unlisted products are covered as custom analyses.
2,527 products match.
| Product | Company | Therapeutic area | Market · date | |
|---|---|---|---|---|
| Noxafil posaconazole | Merck Sharp and Dohme B.V | Candidiasis; Mycoses; Coccidioidomycosis; Aspergillosis | 🇪🇺 EU 2005-10-25 | Order → |
| Posaconazole SP posaconazole | Schering-Plough Europe | Candidiasis; Mycoses; Coccidioidomycosis; Aspergillosis | 🇪🇺 EU 2005-10-25 | Order → |
| Procoralan ivabradine | Les Laboratoires Servier | Angina Pectoris; Heart Failure | 🇪🇺 EU 2005-10-25 | Order → |
| Xolair omalizumab | Novartis Europharm Limited | Asthma; Urticaria; Rhinitis | 🇪🇺 EU 2005-10-25 | Order → |
| Xyrem sodium oxybate | UCB Pharma Ltd | Cataplexy; Narcolepsy | 🇪🇺 EU 2005-10-13 | Order → |
| Ablavar (previously Vasovist) gadofosveset trisodium | TMC Pharma Services Ltd. | Magnetic Resonance Angiography | 🇪🇺 EU 2005-10-03 | Order → |
| Tarceva erlotinib | Cheplapharm Registration GmbH | Carcinoma, Non-Small-Cell Lung; Pancreatic Neoplasms | 🇪🇺 EU 2005-09-19 | Order → |
| Fosavance alendronic acid;colecalciferol | Organon N.V. | Osteoporosis, Postmenopausal | 🇪🇺 EU 2005-08-24 | Order → |
| Aclasta zoledronic acid | Sandoz Pharmaceuticals d.d. | Osteoporosis; Osteitis Deformans; Osteoporosis, Postmenopausal | 🇪🇺 EU 2005-04-15 | Order → |
| Aloxi palonosetron | Helsinn Birex Pharmaceuticals Ltd. | Vomiting; Cancer | 🇪🇺 EU 2005-03-22 | Order → |
| Zonegran zonisamide | Amdipharm Limited | Epilepsies, Partial | 🇪🇺 EU 2005-03-10 | Order → |
| Azilect rasagiline | Teva B.V. | Parkinson Disease | 🇪🇺 EU 2005-02-21 | Order → |
| Orfadin nitisinone | Swedish Orphan Biovitrum International AB | Tyrosinemias | 🇪🇺 EU 2005-02-21 | Order → |
| Prialt ziconotide | Esteve Pharmaceuticals GmbH | Injections, Spinal; Pain | 🇪🇺 EU 2005-02-21 | Order → |
| Truvada emtricitabine;tenofovir disoproxil | Gilead Sciences Ireland UC | HIV Infections | 🇪🇺 EU 2005-02-20 | Order → |
| Quintanrix diphtheria, tetanus, pertussis (whole cell), hepatitis B (rDNA) and Haemophilus influenzae type B conjugate vaccine (absorbed) | GlaxoSmithKline Biologicals S.A. | Hepatitis B; Tetanus; Immunization; Meningitis, Haemophilus; Whooping Cough; Diphtheria | 🇪🇺 EU 2005-02-17 | Order → |
| Fendrix hepatitis B (rDNA) vaccine (adjuvanted, adsorbed) | GlaxoSmithKline Biologicals S.A. | Hepatitis B; Immunization | 🇪🇺 EU 2005-02-02 | Order → |
| Avastin bevacizumab | Roche Registration GmbH | Carcinoma, Non-Small-Cell Lung; Breast Neoplasms; Ovarian Neoplasms; Colorectal Neoplasms; Carcinoma, Renal Cell; Fallopian Tube Neoplasms; Peritoneal Neoplasms | 🇪🇺 EU 2005-01-12 | Order → |
| Cymbalta duloxetine | Eli Lilly Nederland B.V. | Anxiety Disorders; Diabetic Neuropathies; Depressive Disorder, Major | 🇪🇺 EU 2004-12-17 | Order → |
| Nodetrip (previously Xeristar) duloxetine | Esteve Pharmaceuticals, S.A. | Anxiety Disorders; Depressive Disorder, Major; Diabetic Neuropathies | 🇪🇺 EU 2004-12-17 | Order → |
Order a report or brief us
We confirm scope and send the invoice by e-mail; work starts on confirmation.